January 31, 2020

According to the FDA, Philips management, including executives, “were aware of potential foam degradation issues concerning CPAPs, BiPAPs, and Trilogy ventilators” since at least this date, or earlier, but implemented “no further corrective actions until April 2021.” Additionally, the FDA found that the firm became aware of the issue and related field complaints in at least 2015 or earlier.